Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rANDV-44
- Development stage
- Unknown
- Lead developer
- Vanderbilt University Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
rANDV-44 is a recombinant human monoclonal antibody (mAb) developed for the treatment and prevention of Hantavirus Pulmonary Syndrome (HPS) caused by the Andes virus (ANDV). Isolated from the B cells of a survivor of ANDV infection, this antibody specifically targets the envelope glycoproteins (Gn and Gc) of the virus. By binding to these glycoproteins, rANDV-44 neutralizes the virus and prevents its entry into host cells. Preclinical studies in Syrian hamster models have demonstrated that the antibody provides potent post-exposure protection against lethal ANDV challenge. It is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and pharmacokinetics in humans, representing a potential first-in-class therapeutic for this high-fatality infectious disease.
- Other names
- recombinant human monoclonal antibody 44
02
Targets
ANDV (Andes orthohantavirus)
Beyond the preview
Go deeper on rANDV-44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rANDV-44.